Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide

Journal of Clinical Oncology

Volumn 27, Issue 8, 2009, Pages 1257-1261

  Glas, Martin ^a   Happold, Caroline ^a   Rieger, Johannes ^a   Wiewrodt, Dorothee ^a   Bixhr, Oliver ^a   Steinbach, Joachim P ^a   Wick, Wolfgang ^a   Kortmann, Rolf Dieter ^a   Reifenberger, Guido ^a   Weller, Michael ^a   Herrlinger, Ulrich ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; FEMALE; FOLLOW UP; GENE; GLIOBLASTOMA; HUMAN; KARNOFSKY PERFORMANCE STATUS; MALE; METHYLATION; MGMT GENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SEPTICEMIA; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DACARBAZINE; FEMALE; GLIOBLASTOMA; HUMANS; LOMUSTINE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES;

EID: 62449086667     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.2195     Document Type: Article

References (9)

1. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
2. Herrlinger U, Rieger J, Koch D, et al: Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol 24:44124417, 2006
3. Curran WJ, Scott CB, Horton J, et al: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:704-710, 1993
4. Scott CB, Scarantino C, Urtasun R, et al: Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: A report using RTOG 90-06. Int J Radiat Oncol Biol Phys 40:51-55, 1998
5. Mollemann M, Wolter M, Felsberg J, et al: Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 113:379-385, 2005
6. Macdonald DR, Cascino TL, Schold SC Jr, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990
7. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005
8. McLendon RE, Halperin EC: Is the long-term survival of patients with intracranial glioblastoma multiforme overstated? Cancer 98:1745-1748, 2003
9. Krex D, Klink B, Hartmann C, et al: Long-term survival with glioblastoma multiforme. Brain 130: 2596-2606, 2007